Clinical Trial Results:
            A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides pteronyssinus / Lepidoglyphus destructor  and DP/MG/14-2  Dermatophagoides pteronyssinus /Blomia tropicalis) in subjects with allergic rhinitis or rhinoconjunctivitis, with controlled allergic asthma.
    
|     Summary | |
|     EudraCT number | 2014-000172-26 | 
|     Trial protocol | ES | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1 | 
|     This version publication date | 
                                    12 Sep 2021
                             | 
|     First version publication date | 
                                    12 Sep 2021
                             | 
|     Other versions | v2 | 
|     Summary report(s) | Prematurely end | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
